Why the study?
Heteromerization and crosstalk with other receptors can alter GPCR properties and function, adding complexity to the renin-angiotensin system and potentially offering new therapeutic approaches.
Key points are not available for this paper at this time.
Design
Review
Receptor heteromerization may refine RAS pharmacology; leaves open whether targeting oligomers improves outcomes in hypertension or HF.
The renin‐angiotensin system (RAS) plays a key role in blood pressure regulation. The RAS is a complex interconnected system composed of two axes with opposite effects. The pressor arm, represented by angiotensin (Ang) II and the AT 1 receptor (AT 1 R), mediates the vasoconstrictor, proliferative, hypertensive, oxidative, and pro‐inflammatory effects of the RAS, while the depressor/protective arm, represented by Ang‐(1–7), its Mas receptor (MasR) and the AT 2 receptor (AT 2 R), opposes the actions elicited by the pressor arm. The AT 1 R, AT 2 R, and MasR belong to the G‐protein‐coupled receptor (GPCR) family. GPCRs operate not only as monomers, but they can also function in dimeric (homo and hetero) or higher‐order oligomeric states. Due to the interaction with other receptors, GPCR properties may change: receptor affinity, trafficking, signaling, and its biological function may be altered. Thus, heteromerization provides a newly recognized means of modulation of receptor function, as well as crosstalk between GPCRs. This review is focused on angiotensin receptors, and how their properties are influenced by crosstalk with other receptors, adding more complexity to an already complex system and potentially opening up new therapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Gironacci et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: